FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000295132> ?p ?o ?g. }

• W2000295132 abstract "Background: To date, the only FDA approved targeted agent in advanced hepatocarcinomas is sorafenib, indicating a critical need for innovative therapeutic options. LY2157299, a selective ATP-mimetic inhibitor of TGF-β receptor (TβR)-I activation, is currently under clinical investigation in HCC patients after sorafenib or in patients ineligible for sorafenib. Our study aimed at investigating the effects of LY2157299 in HCC cell lines and patient samples with various AFP expression levels.Materials and Methods: Antiproliferative effects of LY2157299 were evaluated in a panel of human HCC cells by MTT assay. Baseline and phosphorylated (p-) protein levels were assessed by Western blot analysis and mRNA expressions by qRT-PCR. Invasion assays were done on matrigel and in OptiCell systems. Tumor samples from HCC patients were surgically resected and cut in 300 µm thick slices using a Tissue Slicer. Each slice was randomly exposed to LY2157299 (1µM and 10µM) and sorafenib (5µM) for 48h. At the end of treatment, tumor samples were analyzed by immunohistochemistry (IHC) or immunofluorescence (IF).Results: LY2157299 was evaluated in HEPG2 and HUH-7 AFP-positive and HEP3B and SK-HEP1 AFP negative cells as well as “in lab-established” SK-HEP1-derived cell lines resistant to the tyrosine kinase inhibitors sorafenib (SK-Sora) and sunitinib (SK-Suni). Exogenous stimulation of all HCC cell lines with TGF-β yielded downstream activation of canonical Smad pathway that was potently inhibited with LY2157299 treatment at micromolar concentrations. In contrast, the non-canonical pathways such as MAPK and Akt/mTOR were not activated by TGF-β in most cell lines with the exception of SK-HEP1 cells where LY2157299 restored the basal level of p-ERK1/2, p-AKT and p-S6 kinase phosphorylation. Low concentrations of LY2157299 displayed antiproliferative effects in HEPG2 and HEP3B cells when stimulated by TGF-β but not in other cell lines. LY2157299 yielded potent anti-migratory and anti-invasive properties in invasive SK-HEP1, SK-Suni and SK-Sora cells. Tumor slices from surgically resected advanced HCC tumor from 5 different patients, were exposed ex vivo to LY2157299 or sorafenib for 48h. This method allows the evaluation of novel anticancer agents in whole tumors containing cancer cells and stromal cells. LY2157299 but not sorafenib decreased 2-5 fold the p-Smad2/3. LY2157299 treatment mainly affected PI3K/AKT rather than MAPK signalling pathway. In contrast, sorafenib treatment reduced both PI3K and MAPK pathway activation. IHC analysis of LY2157299 and sorafenib-exposed samples showed a significant decrease (>3 fold) of the proliferative marker Ki67 and increase of the apoptotic marker caspase-3 (3-5 fold). Interestingly, all molecular effects were independent of AFP expression.Conclusion: TGF-β/TβR-I inactivation using LY2157299 inhibits TGF-β-dependent cell signaling in HCC cell lines with either anti-proliferative or anti-invasive effects depending on the model. In tumor samples from patients, inhibition of TGF-β signaling was associated with inhibition of proliferation and apoptosis induction regardless AFP level. Our data suggest that LY2157299 may be useful for patients with HCC.Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A228.Citation Format: Marie Serova, Annemilai Tijeras-Raballand, Celia Dos Santos, Karim A. Benhadji, Valerie Paradis, Eric Raymond, Sandrine Faivre, Armand de Gramont. TGF-beta signaling inhibition using LY2157299 affects proliferation or invasion in hepatocarcinoma cells and patient samples. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A228." @default.
• W2000295132 created "2016-06-24" @default.
• W2000295132 creator A5002864173 @default.
• W2000295132 creator A5006585898 @default.
• W2000295132 creator A5013952219 @default.
• W2000295132 creator A5035411007 @default.
• W2000295132 creator A5048710140 @default.
• W2000295132 creator A5060705598 @default.
• W2000295132 creator A5063395534 @default.
• W2000295132 creator A5083482017 @default.
• W2000295132 date "2013-11-01" @default.
• W2000295132 modified "2023-09-29" @default.
• W2000295132 title "Abstract A228: TGF-beta signaling inhibition using LY2157299 affects proliferation or invasion in hepatocarcinoma cells and patient samples." @default.
• W2000295132 doi "https://doi.org/10.1158/1535-7163.targ-13-a228" @default.
• W2000295132 hasPublicationYear "2013" @default.
• W2000295132 type Work @default.
• W2000295132 sameAs 2000295132 @default.
• W2000295132 citedByCount "0" @default.
• W2000295132 crossrefType "proceedings-article" @default.
• W2000295132 hasAuthorship W2000295132A5002864173 @default.
• W2000295132 hasAuthorship W2000295132A5006585898 @default.
• W2000295132 hasAuthorship W2000295132A5013952219 @default.
• W2000295132 hasAuthorship W2000295132A5035411007 @default.
• W2000295132 hasAuthorship W2000295132A5048710140 @default.
• W2000295132 hasAuthorship W2000295132A5060705598 @default.
• W2000295132 hasAuthorship W2000295132A5063395534 @default.
• W2000295132 hasAuthorship W2000295132A5083482017 @default.
• W2000295132 hasConcept C104317684 @default.
• W2000295132 hasConcept C121608353 @default.
• W2000295132 hasConcept C126322002 @default.
• W2000295132 hasConcept C142724271 @default.
• W2000295132 hasConcept C153911025 @default.
• W2000295132 hasConcept C204232928 @default.
• W2000295132 hasConcept C2776415932 @default.
• W2000295132 hasConcept C2778019345 @default.
• W2000295132 hasConcept C2778608917 @default.
• W2000295132 hasConcept C2778695046 @default.
• W2000295132 hasConcept C2779490328 @default.
• W2000295132 hasConcept C2780394083 @default.
• W2000295132 hasConcept C2780783641 @default.
• W2000295132 hasConcept C502942594 @default.
• W2000295132 hasConcept C54355233 @default.
• W2000295132 hasConcept C55493867 @default.
• W2000295132 hasConcept C57074206 @default.
• W2000295132 hasConcept C62112901 @default.
• W2000295132 hasConcept C62478195 @default.
• W2000295132 hasConcept C71924100 @default.
• W2000295132 hasConcept C75217442 @default.
• W2000295132 hasConcept C81885089 @default.
• W2000295132 hasConcept C86554907 @default.
• W2000295132 hasConcept C86803240 @default.
• W2000295132 hasConcept C95444343 @default.
• W2000295132 hasConceptScore W2000295132C104317684 @default.
• W2000295132 hasConceptScore W2000295132C121608353 @default.
• W2000295132 hasConceptScore W2000295132C126322002 @default.
• W2000295132 hasConceptScore W2000295132C142724271 @default.
• W2000295132 hasConceptScore W2000295132C153911025 @default.
• W2000295132 hasConceptScore W2000295132C204232928 @default.
• W2000295132 hasConceptScore W2000295132C2776415932 @default.
• W2000295132 hasConceptScore W2000295132C2778019345 @default.
• W2000295132 hasConceptScore W2000295132C2778608917 @default.
• W2000295132 hasConceptScore W2000295132C2778695046 @default.
• W2000295132 hasConceptScore W2000295132C2779490328 @default.
• W2000295132 hasConceptScore W2000295132C2780394083 @default.
• W2000295132 hasConceptScore W2000295132C2780783641 @default.
• W2000295132 hasConceptScore W2000295132C502942594 @default.
• W2000295132 hasConceptScore W2000295132C54355233 @default.
• W2000295132 hasConceptScore W2000295132C55493867 @default.
• W2000295132 hasConceptScore W2000295132C57074206 @default.
• W2000295132 hasConceptScore W2000295132C62112901 @default.
• W2000295132 hasConceptScore W2000295132C62478195 @default.
• W2000295132 hasConceptScore W2000295132C71924100 @default.
• W2000295132 hasConceptScore W2000295132C75217442 @default.
• W2000295132 hasConceptScore W2000295132C81885089 @default.
• W2000295132 hasConceptScore W2000295132C86554907 @default.
• W2000295132 hasConceptScore W2000295132C86803240 @default.
• W2000295132 hasConceptScore W2000295132C95444343 @default.
• W2000295132 hasLocation W20002951321 @default.
• W2000295132 hasOpenAccess W2000295132 @default.
• W2000295132 hasPrimaryLocation W20002951321 @default.
• W2000295132 hasRelatedWork W136039664 @default.
• W2000295132 hasRelatedWork W1492716968 @default.
• W2000295132 hasRelatedWork W1558776379 @default.
• W2000295132 hasRelatedWork W1980808082 @default.
• W2000295132 hasRelatedWork W1993103935 @default.
• W2000295132 hasRelatedWork W1999762017 @default.
• W2000295132 hasRelatedWork W2013210951 @default.
• W2000295132 hasRelatedWork W2085145218 @default.
• W2000295132 hasRelatedWork W2088944779 @default.
• W2000295132 hasRelatedWork W2160339120 @default.
• W2000295132 hasRelatedWork W2257069850 @default.
• W2000295132 hasRelatedWork W2321788886 @default.
• W2000295132 hasRelatedWork W2329037707 @default.
• W2000295132 hasRelatedWork W2335571411 @default.
• W2000295132 hasRelatedWork W2371880494 @default.
• W2000295132 hasRelatedWork W2561680981 @default.
• W2000295132 hasRelatedWork W2563899315 @default.
• W2000295132 hasRelatedWork W3024302037 @default.
• W2000295132 hasRelatedWork W3132520529 @default.
• W2000295132 hasRelatedWork W3152256888 @default.

• next